However, the resistance to imatinib may develop in significant portions of patients under treatment, especially in those with CML in advanced stages or with Ph+ ALL mostly due to the emergence of mutations in the BCR/ABL kinase domain, including the most prevalent E255K and T315I mutations. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.